Search Blog
Categories
May 2018
M T W T F S S
« Apr    
 123456
78910111213
14151617181920
21222324252627
28293031  

Tags

Nick Kohlschreiber – Interlacing Interfaces of Marketing and Tech

By Nick Kohlschreiber

http://nickkohlschreibermarketing.com

ORANGE COUNTY, CA / ACCESSWIRE / May 19, 2018 / Without modern technology, it would be nearly impossible to captivate the interest of consumers who are fully engulfed in the world of social media and digital consumption. Nick Kohlschreiber, a renowned entrepreneur from California, points out that a profound transformation of marketing techniques is already well underway, as consumers spend an increasing amount of time on their smartphones and computers. This has created a challenge for brands as they seek to connect with customers through all these devices in real-time, while also developing advertising campaigns that are effective across social media, display advertising and e-commerce.

Sweeping technological advances and the expansive outreach of social media has permanently altered the nature of marketing as a whole, a sentiment Guardian contributor David Benady noted prior to a panel discussion with industry executives. ”Real-time conversations brands have with people as they interact with websites and mobile apps has changed the nature of marketing,” Benady wrote. ”The modern-day marketing department needs to combine the creative side of the discipline – using powerful narratives to tap into people’s wishes and aspirations – with the technical side of data, digital engineering and analytics.” The potential reach of an advertising campaign has also broadened. Facebook, YouTube, online news websites, and integrated apps for smartphones and tablets now allow strong ideas to quickly spread and influence in the span of a single day. ”If you come up with that nugget of an idea, you’ve now got such reach that you can expand that and get tremendous coverage just from a little niche idea,” said Mark Singleton, head of marketing at betting brand Paddy Power.

Various technological tools enable modern marketing techniques to provide a highly personalized customer experience, often through insightful analytics providing a more targeted audience. As the number of tools and options continues to grow at rapid rates, marketers are faced with increasingly complicated decisions while deciding on their strategy. Nick Kohlschreiber encourages them to carefully weigh the numerous choices available and focus on methods that best fit their brand, while offering the highest level of direct access to their targeted consumer base. Kohlschreiber also advises companies to constantly reevaluate their strategies in light of emerging entities that may ensure even higher degrees of innovative and strategic advertising. By continuing to embrace evolutions in technology, marketing experts can stay ahead of the latest trends, adapting to changes while receiving optimal results.

Nick Kohlschreiber is an experienced businessman and entrepreneur, beginning his career at a young age as the head of marketing at an online wholesale product company, where he invigorated sales with his innovative approach to the online selling and direct shipping of products to its consumers. Now the owner of a media company based in Newport Beach, Kohlschreiber oversees hundreds of employees and tens of thousands of clients every day, while striving to further the connections to the modern communication platforms — from document preparation, to online, multimedia-driven business development. In his spare time, he is a dedicated philanthropist assisting both local charities and various international non-profit organizations.

Nick Kohlschreiber – Expert in Modern Marketing: http://www.nickkohlschreibernews.com

Nick Kohlschreiber – Business Entrepreneur & Founder of TeleTree: http://nickkohlschreiberreviews.com

Nick Kohlschreiber – Creative Marketing Solutions Expert: http://nickkohlschreibermarketing.com

Contact Information

NickKohlschreiberNews.com
www.NickKohlschreiberNews.com
contact@nickkohlschreibernews.com

SOURCE: Nick Kohlschreiber

ReleaseID: 500294

Genesys Fund – on How Innovative Technologies Drive Impact Investing

By GenesysFund

PORT VILA, VANUATU / ACCESSWIRE / May 19, 2018 / Investment in projects for the social good is growing. According to a recent survey by the Global Impact Investing Network, more than 25 billion USD was put into impact investments in 2017, an increase of 17 percent from the year before. Within social investing, there has arisen a thriving niche of ”tech for good” activists who focus on technology start-ups that, while run for profit, are also committed to making a positive impact on society. Genesys Fund, an award winning forex and commodities broker that specializes in finding opportunities for clients to make a positive societal and environmental influence, discusses the tech ventures that are driving impact investing.

”While philanthropy and investments have traditionally been viewed as two distinct areas, there has been a growing synergy in recent years with the ever-increasing popularity of investments seeking to deliver a measurable social benefit,” said Genesys Fund. ”If just one percent of the estimated 80 trillion USD passing through global markets was allocated to impact investing, the capital pool would be about three times larger than the total annual charitable giving in the United States.” According to the previously referenced Global Impact Investing Network report, more than 10 billion USD in impact investing assets already sits in Latin America, and there are arguments that even traditional tech investors buying into startups that attract talent and create jobs are positively affecting the region’s communities. ”The movement is going to redefine capital markets,” said Amit Bhatia, the head of the Global Steering Group for Impact Investing. Bhatia estimates that the global market for socially-conscious investment will grow to 300 billion USD by 2020, reaching more than a billion people in need.

Most importantly, investors in the space are making a profit. The latest annual report from the Social Stock Exchange calculates that impact investment funds have an average internal rate of return of 9.5 percent. ”Profit and returns have a unique meaning in the impact space,” said Genesys Fund. ”Without profit, you don’t have the sustainability to prompt change on a greater scale.” Companies including Digital Mums – a business that helps mothers with in-demand digital skills pursue flexible careers that can fit around family life – and Open Utility – a service that allows people to buy excess solar power from their neighbours – are prime examples of tech ventures that are improving society along with investor portfolios.

Founded in 2016, Genesys Fund is a globally recognized brokerage firm that works alongside philanthropic groups to provide them with investment management services aimed at increasing their impact and ability to act as a force for good. In turn, the company offers like-minded investors the opportunity to have a positive social and environmental impact while increasing returns with their proprietary investment strategies. Genesys Fund’s investment solutions are available for amatuer, wholesale and professional investors, with detailed performance information available upon request.

GenesysFund – The Most Robust Asset Management Offerings Available: http://www.genesysfundnews.com

Genesys Fund – Discusses the Importance of Investing for Retirement: https://finance.yahoo.com/news/genesys-fund-discusses-importance-investing-025000343.html

GenesysFund – Forecasts High Returns in the Money Markets for 2018: https://finance.yahoo.com/news/genesysfund-forecasts-high-returns-money-032500177.html

Contact Information:

GenesysFundNews.com
http://www.genesysfundnews.com
contact@genesysfundnews.com

SOURCE: GenesysFund

ReleaseID: 500293

QSmart Limited – Analyzes Outlook for Forex Market in Asia

By Q Smart Limited

LUXEMBOURG CITY, LUXEMBOURG / ACCESSWIRE / May 19, 2018 / According to the recent IMF World Economic Outlook, the growth of global economy may become a key driver for currencies, stocks and commodities in 2018, primarily due to risk management being closely tied to understanding the evolution of global growth, volatility, and their combined effect on the market. QSmart Limited, a market leading provider of Contracts for Differences, stocks, shares, and indices, as well as a part of FITCo and ARTCORP, shares its thoughts on the favorable outlook for Forex markets in Asia.

Analysts at leading global investment banks Goldman Sachs and Barclays predict global growth to hit 4% in 2018 – the highest mark since 2011 – while U.S. economists classify the outlook as highly beneficial. On the back of the economic growth, Asian currencies are forecasted to be investor favored, further supported by the continued rise of export and policy normalizations in the region. Furthermore, according to a Bloomberg survey involving 20 investors, traders and strategists, bonds and equities in developing Asian countries will continue to outpace their developed-country peers in 2018. ”The environment for emerging markets was great in 2017 with the Goldilocks factors of economic growth and low inflation in industrialized countries,” said Hideo Shimomura, chief fund manager at Mitsubishi UFJ Kokusai Asset Management Co., a leading investment firm, ”The emerging markets rally we saw this year will probably extend into 2018, but after a period of strong growth and low inflation, some adjustment will be inevitable.” While the Federal Reserve remains key to determine the fate of what seems to be the best year for emerging markets since 2009 in terms of stocks and currencies, other factors like Brexit, European Central Bank’s and Bank of Japan’s actions along with the global economic outlook for China may play a significant role.

As noted by QSmart Limited, there are also a couple of industry-wide factors that affect the Asian market outlook: Markets in Financial Instruments Directive ( Mifid) II – a revamp of Mifid, the legislation for the regulation of investment services within the European Economic Area, designed to increase the transparency in all asset classes and offer greater protection to investors – and the global code of conduct – a new set of 55 principles that are meant to replace regional codes with a single blueprint for conduct in the Forex markets. ”One of the most significant factors that will affect the FX market in 2018 will be the implementation of Mifid II. This will impact the market in three primary ways – the migration of trading to regulated platforms, the introduction of extensive reporting obligations and an increase in compliance requirements.” The implementation of the global code of conduct, which happened in early 2017, is expected to redefine the rules of the Forex industry in the current year. ”It is clear that the code is shining a light on areas of the market that have long been overdue for review. Equality, transparency and market conduct have emerged as key industry themes which I feel will continue to dominate discussions over the next year and beyond.” Said Roger Rutherford, chief operating officer at trading platform ParFX.

QSmart Limited is a market leading broker offering CFDs on currencies, indexes, commodities and stocks, specializing in trading of financial products in OTC and organized stock markets. Thanks to advanced technology and a wide selection of modern trading instruments, the company’s clients enjoy a seamless and honest trading experience that continuously delivers transparent and fair results. With the mission to become the number one offline trading platform for both institutional and retail clients, and guided by the determination to deliver world-class service to its clientele, QSmart is dedicated to building loyal and long-lasting relationships via constant innovation and self-evaluation.

Q Smart Limited – Market Leading Supplier of CFDs: http://qsmartlimitednews.com

QSmart Limited on Factors Shaping Commodities Markets: http://markets.financialcontent.com/streetinsider/news/read/36297981

Q Smart Limited – Discusses Factors Driving FinTech Investment: https://finance.yahoo.com/news/q-smart-limited-discusses-factors-021000533.html

Q Smart Limited – Discusses the Advantages of Index Investing: https://finance.yahoo.com/news/q-smart-limited-discusses-advantages-044500931.html

Contact Information:

QSmartLimitedNews.com
contact@qsmartlimitednews.com
http://qsmartlimitednews.com

SOURCE: Q Smart Limited

ReleaseID: 500167

RoseChain Is Planning to Trade Its ICO on Dx.Exchange NASDAQ

By Rose exchange capital LTD

NEW YORK, NY / ACCESSWIRE / May 19, 2018 / Bombshell news: ‘The world’s first cryptocurrency exchange powered by NASDAQ is set to launch next month. DX.exchange, which is powered by NASDAQ’s trading platform, will be a regulated cryptocurrency exchange available through a web app, iOS, and Android.’ https://www.google.com/amp/s/bitcoinexchangeguide.com/nasdaq-powered-dx-cryptocurrency-exchange-will-launch-in-june/amp/ There exists a breathtakingly high profit margin in the digital money market. Faced with a huge market with nearly 6 billion USD profits each year, no exchange will choose to turn a blind eye. ‘It’s important to note that DX isn’t partnering with NASDAQ to launch the exchange. This isn’t the cryptocurrency exchange NASDAQ has long been rumored to be launching. Instead, this is an independent cryptocurrency exchange powered by NASDAQ technology – similar to how traditional stock exchanges worldwide use NASDAQ’s technology.’ https://www.google.com/amp/s/bitcoinexchangeguide.com/nasdaq-powered-dx-cryptocurrency-exchange-will-launch-in-june/amp/

Digital currency has officially stepped from “non-mainstream” into mainstream.

As a benchmark in the financial market industry, the signals sent by NASDAQ are of extremely important referential significance. Its dynamics will influence traditional financial exchanges on a global scale, which will bring about undeniable incentive effect on world capital market operation. This move indicates the increasing global consensus on cryptocurrency and digital assets and rising acceptability of cryptocurrency and digital assets among people in the world. ”THE ADVANTAGE OF THIS COOPERATION IS THREEFOLD,” EXPLAINED DX EXCHANGE CEO DANIEL SKOWRONSKI IN AN INTERVIEW WITH FINANCEMAGNATES. ”THE BRAND NAME, THE TECHNOLOGY AND THE REGULATIONS.” https://www.google.com/amp/s/bitcoinexchangeguide.com/nasdaq-powered-dx-cryptocurrency-exchange-will-launch-in-june/amp/

The digital currency market will be more normative!

NASDAQ as a stock exchange is a traditional, mainstream, and largest financial trading market system, which makes stronger regulatory compliance and stable transaction environment available for the whole digital currency market. Listing on NASDAQ also facilitates the financing of project parties without worrying about ICO legitimation. NASDAQ is famous for its low market access threshold, which will make more excellent projects known to the world and benefit project implementation. From the perspective of investors, they don’t need to worry about the platform exit problem as NASDAQ is the second largest exchange in the world. Despite of the low market admittance, under strong post-mortem supervision, exchanges have great regulatory power to guarantee investors’ interest. In addition, there are large differences of the transaction expense between the currently active transaction platforms. The launch of the NASDAQ Stock Exchange will simplify the whole investment process and make transactions more transparent. Above advantages are obvious what investors like to see. ‘ Using NASDAQ’s platform will also help DX Exchange meet the highest regulatory standards. NASDAQ’s exchange eliminates errors like double count trading. It will also prevent fake volumes.’ https://www.google.com/amp/s/bitcoinexchangeguide.com/nasdaq-powered-dx-cryptocurrency-exchange-will-launch-in-june/amp/

A new round of fortune storm–RoseChain is coming

It is reported that DX will provide a simple process of access to digital currency transactions without charging any transaction fees. Top six cryptocurrencies such as Bitcoin, Bit Cash and Ethereum will be launched in the first phase of the platform operation, 20-25 currencies will be launched in the second phase. As the first decentralization platform based on blockchain technology, the decentralization platform can achieve stem cell medical globalization and stem cell cosmetology globalization. Rosechain is one of them. RoseChain, as the top seed in the blockchain field in 2018, has been fully acknowledged by many industry giants. By then, Rose Chain is doing all effort to its commercial mode and planing to be listed on the second phase cryptocurrencies of DX Exchange. Through mining machine capacity conbines stem cell medical cosmetology commercial applications circulation and NASDAQ transactions, Rose Chain will become a hard-to-get coin.

Rose exchange capital LTD
candy.rosex.pro
rosebos@yeah.net
Lyen

SOURCE: Rose exchange capital LTD

ReleaseID: 499859

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Myriad Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline – MYGN

By Pomerantz LLP

NEW YORK, NY / ACCESSWIRE / May 19, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) and certain of its officers. The class action, filed in United States District Court, District of Utah, and docketed under 18-cv-00336, is on behalf of a class consisting of investors who purchased or otherwise, acquired common shares of Myriad between August 13, 2014, and March 12, 2018, both dates inclusive (the “Class Period”). Plaintiff seeks to recover compensable damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder.

If you are a shareholder who purchased Myriad securities between August 13, 2014, and March 12, 2018, both dates inclusive, you have until June 19, 2018, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at
rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here to join this
class action]

Myriad develops and markets molecular diagnostic products to provide physicians with information to help guide the care of their patients, to prevent disease, delay the onset of disease, and catch disease at an early stage. Myriad purports to employ a variety of proprietary techniques designed to provide an understanding of the genetic basis of disease and the role of genes in the onset, progression, and treatment of disease.

Established in 1978, the Healthcare Common Procedure Coding System (“HCPCS”) provides a standardized coding system for describing the specific items and services provided in healthcare. HCPCS dictates the billing codes in the claims that physicians, healthcare providers and suppliers, such as Myriad, submit to the Centers for Medicare and Medicaid Services (“CMS”). The National Correct Coding Initiative (“NCCI”), a CMS program designed to prevent improper payment of procedures that should not be submitted together, provides further instruction with respect to correct billing practices. Among other things, the NCCI provides that billing documents must contain numerical code pairs, reflected in adjacent columns, identifying the services provided. As CMS has stated in its billing guidance documents, “[t]he underlying principle is that the second code defines a subset of the work of the first code. Reporting the codes separately is inappropriate. Separate reporting would trigger a separate payment and would constitute double billing.”

In September 2013, Myriad launched its proprietary 25-gene myRisk Hereditary Cancer test (“myRisk”), which includes testing for multiple genes associated with cancer, including BRCA1 and BRCA2, both of which are associated with breast and ovarian cancer. BRCA1 and BRCA2 genetic testing-specifically, BRCA sequencing and BRCA duplication-deletion – are represented in HCPCS by codes 81211 and 81213. CMS has clearly stated that codes 81211 and 81213 are not correctly used together in claim submissions.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Myriad was submitting false or otherwise improper claims for payment under Medicare and Medicaid for the Company’s hereditary cancer testing; (ii) the foregoing conduct would foreseeably subject Myriad to heightened regulatory scrutiny and/or enforcement action; (iii) Myriad’s revenues from its hereditary cancer testing were in part the product of improper conduct and unlikely to be sustainable; and (iv) as a result, Myriad’s public statements were materially false and misleading at all relevant times.

On March 12, 2018, post-market, Myriad disclosed that it had received a subpoena from the Department of Health and Human Services, Office of Inspector General, in connection with “an investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid,” specifically relating to Myriad’s hereditary cancer testing. The subpoena covers a time period from January 1, 2014 – less than four months after the September 2013 launch of Myriad’s myRisk test – through the date of the subpoena’s issuance.

On this news, Myriad’s share price fell $4.01, or 12.14%, to close at $29.01 on March 13, 2018.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

SOURCE: Pomerantz LLP

ReleaseID: 500184

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Colony NorthStar, Inc. of Class Action Lawsuit and Upcoming Deadline – CLNS

By Pomerantz LLP

NEW YORK, NY / ACCESSWIRE / May 19, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against Colony NorthStar, Inc. (“Colony NorthStar” or the “Company”) (NYSE: CLNS) and certain of its officers. The class action, filed in United States District Court, Central District of California, and docketed under 18-cv-03520, is on behalf of a class consisting of investors who purchased or otherwise acquired Colony NorthStar securities between February 28, 2017, through March 1, 2018, both dates inclusive (the “Class Period”). Plaintiff seeks to recover compensable damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder.

If you are a shareholder who purchased Colony NorthStar securities between February 28, 2017, and March 1, 2018, both dates inclusive, you have until June 5, 2018, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here to join this class action]

Colony NorthStar operates as a real estate investment trust. The Company invests in healthcare, industrial, and hospitality sectors, as well as offers equity and debt management services. Colony NorthStar serves customers globally. The Company resulted from the January 2017 merger between Colony Capital, Inc., NorthStar Asset Management Group Inc. and NorthStar Realty Finance Corp.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Colony NorthStar’s Healthcare and Investment Management segments were performing worse than reported; and (ii) as a result, Colony NorthStar’s public statements were materially false and misleading at all relevant times.

On March 1, 2018, Colony NorthStar reported its financial and operating results for the quarter and year ended December 31, 2017, announcing a goodwill impairment of $375 million, attributable to the Company’s Healthcare and Investment Management segments.

On this news, Colony NorthStar’s share price fell $1.78, or 22.88%, to close at $6.00 on March 1, 2018.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

SOURCE: Pomerantz LLP

ReleaseID: 500185

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Esperion Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – ESPR

By Pomerantz LLP

NEW YORK, NY / ACCESSWIRE / May 19, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against Esperion Therapeutics, Inc. (“Esperion” or the “Company”) (NASDAQ: ESPR) and certain of its officers. The class action, filed in United States District Court, Eastern District of Michigan, and docketed under 18-cv-11438, is on behalf of a class consisting of investors who purchased or otherwise acquired Esperion securities between February 22, 2017 and May 1, 2018, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are a shareholder who purchased Esperion securities between February 22, 2017, and May 1, 2018, both dates inclusive, you have until July 6, 2018, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here to join this class action]

Esperion is a biopharmaceutical company that is primarily focused on the research and development of oral and small molecule therapies for the treatment of patients with elevated levels of low-density lipoprotein cholesterol and other cardio metabolic risk factors. Bempedoic acid and its lead product candidate, the bempedoic acid / ezetimibe combination pill, are targeted therapies focused on reducing elevated LDL-C levels in patients with hypercholesterolemia. The Company owns the exclude worldwide rights to bempedoic acid.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Esperion’s cholesterol-lowering medication, bempedoic acid, entailed serious undisclosed safety risks, including death; and (ii) as a result of the foregoing, Esperion’s public statements were materially false and misleading at all relevant times.

On May 2, 2018, Esperion announced results from its second pivotal Phase 3 study for its cholesterol-lowering medication. Esperion reported that while the trial met the primary endpoint of safety and tolerability and the key efficacy endpoint, there were 13 deaths in the treatment group compared to only two in the control group.

On this news, Esperion’s share price fell $24.75, or 35.10%, to close at $45.75 on May 2, 2018.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

SOURCE: Pomerantz LLP

ReleaseID: 500181

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cancer Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline – CGIX

By Pomerantz LLP

NEW YORK, NY / ACCESSWIRE / May 19, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against Cancer Genetics, Inc. (“Cancer Genetics” or the “Company”) (NASDAQ: CGIX) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 18-cv-06353, is on behalf of a class consisting of investors who purchased or otherwise acquired Cancer Genetics securities between March 23, 2017 through April 2, 2018, both dates inclusive (the “Class Period”), seeking to recover damages caused by defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are a shareholder who purchased Cancer Genetics securities between March 23, 2017, and April 2, 2018, both dates inclusive, you have until June 4, 2018, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at
rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click
here to join this class action]

Cancer Genetics is a diagnostics company focused on the development and commercialization of proprietary genomic tests and services to improve the diagnosis, prognosis, and response to treatment (theranosis) of cancer.

On October 12, 2015, Cancer Genetics issued a press release entitled, “Cancer Genetics, Inc. Finalizes Purchase of Los Angeles-based Molecular Profiling Laboratory, Response Genetics, Inc., Adding $10-$12M in Annual Revenue and Establishing a National Clinical Sales Footprint” which announced that Cancer Genetics closed its acquisition of Response Genetics, Inc., a molecular profiling laboratory, on October 9, 2012.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Cancer Genetics had ineffective disclosure controls and internal controls over financial reporting; and (ii) as a result of the foregoing, Cancer Genetics’ public statements were materially false and misleading at all relevant times.

On April 2, 2018, after the market closed, Cancer Genetics filed its Annual Report on Form 10-K with the Securities and Exchange Commission (“SEC”), announcing the Company’s financial and operating results for the quarter and year ended December 31, 2017 (the “2017 10-K”). The 2017 10-K discussed the Company’s controls over financial reporting, stating in relevant part: “[W]e evaluated, under the supervision and with the participation of our principal executive officer and principal financial officer, the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a 15(e) and 15d-15(e) under the Exchange Act, as amended as of December 31, 2017, the end of the period covered by this report on Form 10-K. Based on this evaluation, the principal executive officer and the principal financial officer have concluded that our disclosure controls and procedures were not effective at December 31, 2017, as a result of the material weakness in internal controls described below. Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and were operating in an effective manner for the period covered by this report, and (ii) is accumulated and communicated to management, including, the principal executive officer and principal financial officer, or the person performing similar functions as appropriate, to allow timely decisions regarding required disclosures.”

Further, on April 2, 2018, after the market closed, Cancer Genetics issued a press release entitled “Cancer Genetics Reports Fourth Quarter and Full Year 2017, Financial Results and Provides Strategic Business Updates.” The press release discussed the fourth quarter and full year 2017 financial results, stating in relevant part: “[A] major area of concentrated focus during the first quarter of 2018 was the careful evaluation of the Company’s accounts receivables, which had increased to approximately $16 million on the balance sheet prior to any adjustments. A significant reason for the increase was disruptions in collections in its Clinical Services business. While the Company continues with its collections efforts on all claims, in the fourth quarter it recorded a bad debt expense of $4.4 million and wrote off $1.8 million of its accounts receivable, with a significant portion of the bad debt expense and write off related to collection issues with respect to the accounts receivable recorded subsequent to the 2015 acquisition of Response Genetics Inc.”

On this news, Cancer Genetics’ share price fell $0.55, or over 33.3%, to close at $1.10 per share on April 3, 2018, damaging investors.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

SOURCE: Pomerantz LLP

ReleaseID: 500188

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholder with Losses on their Investment in Synacor, Inc. of Class Action Lawsuit and Upcoming Deadline – SYNC

By Pomerantz LLP

NEW YORK, NY / ACCESSWIRE / May 19, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against Synacor, Inc. (“Synacor” or the “Company”) (NASDAQ: SYNC) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and docketed under 18-cv-02979, is on behalf of a class consisting of investors who purchased or otherwise acquired Synacor securities between May 4, 2016 and March 15, 2018, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are a shareholder who purchased Synacor securities between May 4, 2016, and March 15, 2018, both dates inclusive, you have until June 4, 2018, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here to
join this class action]

Synacor operates as a technology development, multiplatform services, and revenue partner for video, Internet, and communications providers, as well as device manufacturers, governments, and enterprises.

On May 4, 2016, Synacor announced that it had secured a three-year contract to host web and mobile services for AT&T Inc. (“AT&T” and the “AT&T Contract”, respectively).

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Synacor was unlikely to receive significant revenues from the AT&T Contract until 2018; (ii) as such, the Company’s revenue forecasts issued during the Class Period were materially false and misleading; and (iii) as a result of the foregoing, Synacor shares traded at artificially inflated prices during the Class Period, and class members suffered significant losses and damages.

On August 9, 2017, post-market, Synacor issued a press release entitled “Synacor Exceeds Second-Quarter 2017 Financial Guidance; Remains on Path to ‘3/30/300,'” announcing its financial results for the quarter ended June 30, 2017. The press release stated in relevant part: “[T]he joint AT&T-Synacor team has made the strategic decision to prioritize portal engagement right now over monetization. We are seeing the results of this focus in deeper engagement metrics. We are already generating revenue from this new consumer experience, but we expect that additional monetization tactics will be turned on at a more deliberate pace, which will result in a longer ramp to full monetization. As a result, a significant portion of the revenue that we were expecting in Q3 and Q4 this year is delayed to 2018, and we are adjusting our financial guidance for 2017 accordingly. We believe that this engagement-focused strategy ultimately leads to a stronger, more sustainable business,” concluded Bhise.

On this news, Synacor’s share price fell $1.15, or 32.39%, to close at $2.40 on August 10, 2017.

On March 15, 2018, post-market, Synacor held a conference call with analysts and investors to discuss the Company’s fourth-quarter earnings. During the call, Defendant Bhise discussed the shortcomings of the AT&T contract.

On this news, Synacor’s share price fell $0.30, or 14.63%, to close at $1.75 on March 16, 2018.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

SOURCE: Pomerantz LLP

ReleaseID: 500189

Nirvana XP To Launch Nirvana XP Analytics and Nirvana XP Driver At Booth #6970 at the NRA Show 2018 

The solutions are available from Nirvana XP and will be shown at NRA, McCormick Place, Chicago, Il, May 19-22 at booth ##6970.

CHICAGO, IL, May 19, 2018 /24-7PressRelease/ — Nirvana XP, an enterprise restaurant management platform, will launch its Analytics App and Driver app at Booth #6970 at the National Restaurant Association’s NRA Show (May 19-22) in Chicago.

Nirvana XP founder & CEO Kris Parikh said, “This is our fourth year attending the NRA Show, and we are thrilled to showcase many of our new applications and features, including the most comprehensive restaurant analytics and reporting app, Nirvana XP Analytics as well as the one-of-a-kind Driver app.”

The solutions are available from Nirvana XP and will be shown at NRA, McCormick Place, Chicago, Il, May 19-22 at booth ##6970.

“Today’s restaurants increasingly depend on restaurant management software to perform at peak efficiency and maximize revenue. Our business intelligence (BI) app, Nirvana XP Analytics is at the heart of this fundamental shift.”

Nirvana XP’s restaurant analytics application is built on Nirvana XP platform which provides an in-depth analysis of the business, allowing your restaurant to deliver the revenue growth, operational efficiency, identify any issues before they become problems, and drive the ultimate customer experience based on accurate, real-time data.

“The Nirvana XP Analytics app is a Business Intelligence (BI) and Artificial Intelligence tool that will help you improve business performance and better decisions, based on real data. The analysis is available for Metrics on a Daily, Week To Date (WTD), Month To Date(MTD), Year to Date (YTD), Year over Year (YOY) basis. There are endless possibilities to the data BI can analyze.” Kris added.

Kris defines BI in simple terms: BI provides a 360-degree view of the business so executives can make decisions based on real-time, accurate facts and data rather than instinct or hunch, thereby improving efficiencies and maximizing revenue.”

” Any restaurant owner still playing the guessing game is likely losing time and money,” he added.

Nirvana XP is also rolling out their Driver app to support their delivery system.

“Restaurants are putting both money and food handling controls into the hands of third-party delivery companies. Our Driver app’s seamless integration with Nirvana XP Business application is the perfect solution to address this growing challenge for foodservice operators. Restaurants can have their own delivery drivers, reduce costs and prevent mishandling of food. This is a big breakthrough for restaurants as food delivery has become the norm,” Kris said.

Additionally, Nirvana XP’s Self Service Kiosk will also be on display at the NRA Show 2018. It supports multiple locations and currencies with order management and customer engagement benefits, including features like in-store walk in, in-store bar tab, pickup, delivery, check-in, reservations, waitlist, order status, order status tracking, order level feedback and other features.

Press Inquiries: We are at Booth #6970 at the National Restaurant Association’s NRA Show (May 19-22) in Chicago, Illinois.

Email pr@nirvanaxp.com or call Geetika Sahni at 702-303-2250 to schedule an interview with the Nirvana XP”s founder, Kris Parikh.

About Nirvana XP: Nirvana XPTM is an Enterprise Restaurant Management Platform, a truly intuitive, single, mobile application platform for all your business needs. It brings multiple applications onto one simplified platform. Founder Kris Parikh developed a quick, intuitive, truly integrated, and secure mobile application platform by combining cloud-based technology and mobility. Nirvana XP offers an all-in-one, feature-rich, fully customizable, and affordable solution for business owners with integrated order management and performance, smooth inventory tracking, customer relationship management, and real-time cloud reporting.

Fully customizable, the current product offering focuses on full-service restaurants, quick service restaurants, cafes, coffee shops and similar businesses utilizing mobile, iPad and Android tablet devices. For more information and a free trial, go to http://www.nirvanaxp.com/

Connect with Nirvana XP on Facebook (http://www.facebook.com/GetNirvanaXP) and Twitter (http://twitter.com/GetNirvanaXP)